Celldex Therapeutics, Inc.
CLDX
$32.53
$0.531.66%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -87.60% | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -87.60% | -- | |||
| Cost of Revenue | -3.10% | 19.71% | |||
| Gross Profit | 2.96% | -19.52% | |||
| SG&A Expenses | -4.12% | 11.74% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -3.24% | 18.55% | |||
| Operating Income | 3.12% | -18.39% | |||
| Income Before Tax | 3.24% | -21.29% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 3.24% | -21.29% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 3.24% | -21.29% | |||
| EBIT | 3.12% | -18.39% | |||
| EBITDA | 3.19% | -18.61% | |||
| EPS Basic | 3.34% | -21.16% | |||
| Normalized Basic EPS | 3.35% | -21.16% | |||
| EPS Diluted | 3.34% | -21.16% | |||
| Normalized Diluted EPS | 3.35% | -21.16% | |||
| Average Basic Shares Outstanding | 0.12% | 0.10% | |||
| Average Diluted Shares Outstanding | 0.12% | 0.10% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||